India Pharma Outlook Team | Thursday, 13 November 2025
The Pan American Health Organization (PAHO) has placed a $4.75 million (Rs 41 crore) order with Panacea Biotec to supply the Easyfive TT vaccine under a long-term contract. Diphtheria, Haemophilus influenzae type B, Hepatitis-B, pertussis, and tetanus are among the serious illnesses that Easyfive TT actively immunizes against.The Easyfive TT vaccination will be supplied by the corporation in 2026 and 2027.
Panacea Biotec is a biotechnology company that conducts research, development, production, and marketing of vaccines in India and other countries.
Also Read: WHO Adds Sunscreen to Essential Medicines List
Compared to a net loss of Rs 15.80 crore in Q1 FY25, the company posted a consolidated net profit of Rs 4.05 crore in Q1 FY26. In Q1 FY26, operating revenue increased by 44.1% year over year to Rs 166.70 crore.
Highly innovative prescription medications in specialized therapeutic areas like pain, diabetes and cardiovascular management, oncology, renal disease, osteoporosis treatment, and gastrointestinal care are part of the international pharmaceutical formulations product line. In 2011, Celegene USA introduced "PacliAll," our first nanotechnology-based product (Paclitaxel in protein-bound particles), which was the first generic version of Abraxane in history.
In around 30 markets in the CIS, Latin America, Middle East, Asia, and Africa, Panacea Biotec has solidified its position.
One of the biggest vaccine manufacturers in India, Panacea Biotec has received recognition from the UN Health Agencies for collaborating with the Global Polio Eradication Initiative (GPEI) to supply billions of doses of WHO Pre-qualified Polio vaccines in over 50 countries worldwide as a follow-up to the completion of the full range of oral polio vaccines (tOPV, mOPV1, mOPV3, & bOPV (Type1&Type3).
In 2005, Panacea Biotec became the first business to create EasyFive, a totally liquid Pentavalent vaccination (DTwP-Hep B+Hib). As of March 2022, more than 75 nations worldwide were using the WHO-prequalified EasyFive vaccination.
